Antibe Therapeutics Inc(Pre-Merger) ATBPF

Healthcare

Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.

GREY:ATBPF - Post by User

Antibe Therapeutics Inc(Pre-Merger) > Rheumatoid Arthritis and Ankylosing Spondylitis

<< Previous

Bullboard Posts

Next >>

Comment by bringon10baggeron Nov 17, 2020 5:28pm

174 Views

Post# 31919009

RE:Rheumatoid Arthritis and Ankylosing Spondylitis

Next catalyst, expect the MC to be meaningful......finally executing to reflect the true value........thumbs up Dan...

mstrmnd wrote: Corporate deck (page 12):

"Lead indication: osteoarthritis (OA), to be broadened to include rheumatoid arthritis, ankylosing spondylitis, and other acute and chronic pain indications"

Officially additional indications beyond osteoarthritis in the deck. They didn't say how they are going to do this, but the market cap surely went up.

ATB-346 is not just an anti-inflammatory with the best GI safety on the market, it's officially a GI safe anti-inflammatory for inflammatory diseases. Comes with the #1 scientist in the field in the world and is totally derisked with high quality Phase 2a and 2b trials with high statistical significance proving H2S concept that a slam dunk in Phase 3 trials is pretty much guaranteed.

ATB-346 prior market cap: osteoarthritis
ATB-346 new market cap: osteoarthritis, rheumatoid arthritis, ankylosing spondylitis

Broadening indications for ATB-346 could yield better and more timely returns than ATB-352.

This is going to be very exciting! GLTA